logo

News

    • 12 FEB 2020

    PharmaCyte Biotech Receives Certificates of Analysis and Batch Records for its Clinical Trial Product in Pancreatic Cancer

    LAGUNA HILLS, CA February 12, 2020 (BUSINESS NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has received the Certificates of Analysis and the records from both batches of its clinical trial product manufactured

    Read more →
    • 22 JAN 2020

    PharmaCyte Biotech Successfully Completes All Release Tests on Clinical Trial Product

      LAGUNA HILLS, CA January 22, 2019 (BUSINESS NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that both batches of the company’s manufactured clinical trial product have undergone and passed all 10 of the necessary

    Read more →
    • 23 DEC 2019

    PharmaCyte Biotech Passing All Completed Tests on Clinical Trial Product

    LAGUNA HILLS, CA December 23, 2019 (BUSINESS NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that both batches of the company’s manufactured clinical trial product have now passed 7 of the 10 completed “release tests”

    Read more →
    • 19 DEC 2019

    PharmaCyte Biotech Provides Details on Quarterly Shareholder Update

    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its quarterly shareholder update that is scheduled for December 20, 2019, at 4 P.M. EST must be rescheduled. The company’s resources are fully engaged

    Read more →
    • 10 DEC 2019

    PharmaCyte Biotech to Hold Quarterly Shareholder Update

    LAGUNA HILLS, CA December 10, 2019 (BUSINESS NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its quarterly shareholder update will be held on December 20, 2019, at 4:00 P.M. EST. The update will include

    Read more →
    • 25 NOV 2019

    PharmaCyte Biotech “Release Testing” Successful on All Completed Tests of Clinical Trial Product

    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today an update on the completed tests that are part of the U.S. Food and Drug Administration (FDA) required “release testing” related to the company’s first

    Read more →
    • 18 NOV 2019

    PharmaCyte Biotech Successfully Completes Final Manufacturing Run of Clinical Trial Product

    LAGUNA HILLS, CA 18, 2019 (BUSINESS NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its partner, Austrianova Singapore (Austrianova), has successfully completed the second and final GMP manufacturing run to produce PharmaCyte’s clinical trial

    Read more →
    • 04 NOV 2019

    PharmaCyte Biotech Closer to Submitting IND by Successfully Completing Encapsulation of Second Manufacturing Run of Clinical Trial Product

    LAGUNA HILLS, CA November 4, 2019 (BUSINESS NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, is closer to submitting an Investigational New Drug application (IND) to the U.S. Food & Drug Administration (FDA). PharmaCyte announced today that

    Read more →
    • 14 OCT 2019

    PharmaCyte Biotech Successfully Completes Manufacturing of Clinical Trial Product

    LAGUNA HILLS, CA October 14, 2019 (BUSINESS NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its partner, Austrianova Singapore (Austrianova), has completed the first of two staggered and back to back manufacturing runs for

    Read more →
    • 01 OCT 2019

    PharmaCyte Biotech Q&A Discussion with Cellular Biologist David A. Judd

    LAGUNA HILLS, CA October 1, 2019 (BUSINESS NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the latest in its series of Q&A articles that are conducted with some of the key team members of PharmaCyte’s

    Read more →

Subscribe to Our Mailing List

* indicates required
Email Format